IPO Details
| IPO Date | 15 to 19 Oct, 2026 |
| Listing Date | Fri, Oct 23, 2026 |
| Face Value | ₹ 1 per share |
| Sale Type | OFS only |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Total Issue Size | 2,76,44,231 shares (agg. up to ₹ [.] Cr) |
| Offer for Sale | 2,76,44,231 shares of ₹ 1 (agg. up to ₹ [.] Cr) |
| Share Holding Pre Issue | 10,16,46,778 shares |
| Share Holding Post Issue | 10,16,46,778 shares |
IPO Important Dates
| IPO Open | Thu, Oct 15, 2026 |
| IPO Close | Mon, Oct 19, 2026 |
| Allotment | Wed, Oct 21, 2026 |
| Refund | Thu, Oct 22, 2026 |
| Credit of Shares | Thu, Oct 22, 2026 |
| Listing | Fri, Oct 23, 2026 |
Financial Information
| Assets | 1,309.00 | 1,276.43 | 1,094.90 | 970.58 |
| Total Income | 354.33 | 1,218.73 | 1,035.96 | 908.59 |
| Profit After Tax | 15.09 | 69.08 | 25.15 | -7.35 |
| EBITDA | 48.58 | 170.66 | 128.02 | 110.05 |
| NET Worth | 631.72 | 616.05 | 545.23 | 526.30 |
| Reserves and Surplus | 706.86 | 692.48 | 580.71 | 556.57 |
| Total Borrowing | 320.63 | 269.53 | 224.96 | 175.27 |
Key Performance Indicator
| ROE | 2.07% |
| ROCE | 3.16% |
| Debt/Equity | 0.33 |
| RoNW | 2.31% |
| PAT Margin | 4.29% |
| EBITDA Margin | 13.81% |
| NAV | 64.35 |
Information about company
Founded in 2001 by Mr. Dhirajlal Kotadia, Sahajanand Medical Technologies Ltd. is a medical device company focused on Class III and Class C/D devices, primarily in the fields of vascular and structural heart intervention. The company was the first globally to receive CE certification for a drug-eluting stent (DES) with a biodegradable polymer—Infinnium.
The product portfolio spans three key categories:
Sahajanand operates two R&D centers—one in India and one in Thailand—supported by a team of 102 professionals, including biomedical engineers and clinical research specialists. The company has built a robust intellectual property base, with 102 patents granted globally and 71 pending patent applications, along with five design registrations in India.
Key products such as Supraflex Cruz (DES) , Hydra (TAVI) , and Cocoon (Occluders) are backed by 72 clinical studies, and are widely accepted in over 76 countries across Europe, Asia, and other regions. The global distribution strategy includes direct operations in key European markets (Germany, Spain, France, UK), hybrid models in India (serving hospitals like Narayana Hrudayalaya Limited), and distributor-led entry in markets such as Italy.
International market adoption is reinforced by endorsements from key opinion leaders (KOLs), successful government tenders, and partnerships with major Group Purchasing Organizations (GPOs) in Europe.
The company follows a “House of Brand” strategy, developing and commercializing clinically differentiated products under recognized brand names like Supraflex Cruz, Hydra, and Cocoon.
As of March 31, 2025, Sahajanand Medical Technologies employed 1,458 full-time staff, 24 consultants, and 818 contract-based personnel across its operations.
Objectives of IPO
The Sahajanand Medical Technologies Ltd. IPO is a 100% Offer for Sale (OFS), so the company will not receive any funding and the entire IPO proceeds will go to the selling shareholders.
Disclaimer
All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions.
We are not a SEBI Registered analyst. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on Information published on this application.
No financial information whatsoever published anywhere, within this application, should be considered as advice to buy or sell securities or invest in IPOs, or as a guide to doing so in any way whatsoever
Please read all Tearms and conditions , and agree to use the App
Day Wise GMP
IPO Reservation
| QIB | Not more than 50% of the Net Offer |
| Retail | Not less than 35% of the Net Offer |
| NII | Not less than 15% of the Net Offer |
